Naperville, IL -- (SBWire) -- 09/06/2013 --Reportstack, provider of premium market research reports announces the addition of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013 market report to its offering
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013

Summary

, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Bristol-Myers Squibb Company
Genzyme Corporation
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Amgen Inc.
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Seattle Genetics, Inc.
Genentech, Inc.
Gilead Sciences, Inc.
Daiichi Sankyo Company, Ltd
medac GmbH
Merck & Co., Inc.
Gamida Cell Ltd.
Generex Biotechnology Corporation
Plexxikon Inc.
BioLineRx, Ltd.
Bio-Path Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Eisai Co., Ltd.
Pfizer Inc.
Sunesis Pharmaceuticals, Inc.
SuperGen, Inc.
Teva Pharmaceutical Industries Limited
Cell Therapeutics, Inc.
Aduro BioTech
Cyclacel Pharmaceuticals Inc.
Celgene Corporation
Incyte Corporation
Merck KGaA
4SC AG
EntreMed, Inc.
EpiCept Corporation
Celldex Therapeutics, Inc.
IMMUNOMEDICS, INC
Ariad Pharmaceuticals, Inc.
Lorus Therapeutics Inc
Marshall Edwards, Inc.
MethylGene Inc
OXiGENE, Inc.
Critical Outcome Technologies Inc.
CSL Limited
Telik, Inc.
TopoTarget A/S
VioQuest Pharmaceuticals, Inc.
Lipoxen PLC
Choongwae Pharma Corp
Resverlogix Corp.
Synta Pharmaceuticals Corp.
BioAlliance Pharma SA
Sareum Holdings plc
Innate Pharma SA
Oscotec Inc.
Stem Cell Therapeutics Corp.
SymBio Pharmaceuticals Limited
Cellerant Therapeutics, Inc.
Antigen Express, Inc.
Cancer Research Technology Limited
Chroma Therapeutics Ltd.
Colby Pharmaceutical Company
Ambit Biosciences Corporation
Actinium Pharmaceuticals, Inc.
BioMAS Ltd.
Oncodesign SA
ERYtech Pharma
Celator Pharmaceuticals, Inc.
Altor BioScience Corporation
Ascenta Therapeutics, Inc.
Coronado Biosciences, Inc.
Agios Pharmaceuticals
TetraLogic Pharmaceuticals
Deciphera Pharmaceuticals, LLC
Affichem
Stemline Therapeutics, Inc.
Proacta, Inc.
Cornerstone Pharmaceuticals, Inc.
Advenchen Laboratories, LLC
Onconova Therapeutics, Inc
Syndax Pharmaceuticals, Inc.
NovaLead Pharma Pvt. Ltd.
Esperance Pharmaceuticals, Inc.
Trillium Therapeutics Inc.
SBI Biotech Co., Ltd.
KaloBios Pharmaceuticals, Inc.
Aprea AB.
Kinex Pharmaceuticals, LLC
OncoImmune, Inc.
GlycoMimetics, Inc.
Merus B.V.
Toko Pharmaceutical Industries Co., Ltd.
Cancer Therapeutics CRC Pty Ltd
Interprotein Corporation
EpiZyme, Inc.
Targa Therapeutics Corp.
NuCana BioMed Limited
Sentinel Oncology Limited
BerGenBio AS

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/140878/acute-myelocytic-leukemia-aml-acute-myeloblastic-leukemia-pipeline-review-h2-2013.html